| Title |
Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
|
|---|---|
| Published in |
Drug Design, Development and Therapy, October 2016
|
| DOI | 10.2147/dddt.s85050 |
| Pubmed ID | |
| Authors |
Dilek Keskin, Sevil Sadri, Ahmet Emre Eskazan |
| Abstract |
Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib resistance and/or intolerance, as well as in the frontline setting in patients with chronic myeloid leukemia-chronic phase, and also in patients with advanced disease. It is also utilized in Philadelphia chromosome-positive acute lymphocytic leukemia. While choosing the appropriate tyrosine kinase inhibitor (ie, dasatinib) for each individual patient, comorbidities and BCR-ABL1 kinase domain mutations should always be taken into consideration, among other things. This review mainly focuses on patient selection prior to dasatinib administration in the treatment of chronic myeloid leukemia. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Practitioners (doctors, other healthcare professionals) | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 56 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 21% |
| Student > Bachelor | 8 | 14% |
| Other | 4 | 7% |
| Researcher | 4 | 7% |
| Lecturer | 2 | 4% |
| Other | 7 | 13% |
| Unknown | 19 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 18% |
| Biochemistry, Genetics and Molecular Biology | 9 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 9% |
| Immunology and Microbiology | 2 | 4% |
| Neuroscience | 2 | 4% |
| Other | 6 | 11% |
| Unknown | 22 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2016.
All research outputs
#15,089,820
of 25,371,288 outputs
Outputs from Drug Design, Development and Therapy
#813
of 2,268 outputs
Outputs of similar age
#182,417
of 332,549 outputs
Outputs of similar age from Drug Design, Development and Therapy
#28
of 62 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,549 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.